Background: Due to the high failure rate observed in the clinical treatment of morbid obesity
an increase in bariatric surgery indications, as an alternative for the control of
obesity and comorbidities, is noticeable. Aim: To evaluate the performance of type 2 diabetes mellitus, high blood pressure and
dyslipidemia in patients submitted to Roux-en-Y gastric bypass in late follow-up.
Methods:Retrospective analysis of 59 patients included in the bariatric surgery program.
Anthropometric (height and body weight) and laboratory (LDLc, HDLc, VLDLc,
triglyceride -TG - and glucose) data were collected on pre- and postoperative
stages, through medical records. Results: Among the patients, 86% were female aged 43±11, of whom 52% had attended high
school. The average postoperative time was 7±3 years. During the postoperative
period, there were decreases of weight and body mass index, respectively (133±06
kg vs 91±04 kg p<0.05 e 49±74 kg/m2 vs 33±79 kg/m2,
p<0.05). In comparison to the preoperative stage, lower concentrations of
glucose (101.00±26.99 vs 89,11±15.19, p=0.014), total cholesterol rates
(179.00±37,95 vs 167.48±28,50, p=0.016), LDLc (104.30±33.12 vs 91.46±24.58,
p=0.016), VLDLc (25.40±11,12 vs 15.68±7.40, p<0.01), and TG (143.35±86.35 vs
82.45±37.39, p<0.01) and higher concentrations of HDLc (43.53±8.23 vs
57.90±15.60, p<0.01) were identified in the postoperative stage. 40% of
hypertensive patients were still undergoing high blood pressure treatment during
the postoperative stage. There was remission of type 2 diabetes mellitus and
dyslipidemia on 81% and 94% of the cases, respectively. Conclusion: Roux-en-Y gastric bypass has proven itself to be an effective long term
procedure, promoting weight loss, remission of DM2 and dyslipidemia.